# Substance Use in Supportive Oncology and Its Impact on Clinical Outcomes and Care > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/substance-use-supportive-oncology-impact-outcomes/ > **Published:** 2026-03-27T13:05:56-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:36:44-04:00 > **Clinical Summary:** Explore how substance use in supportive oncology affects clinical outcomes, treatment adherence, and patient care in cancer management. --- CED Clinical Relevance  #62Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. 🔬 Evidence Watch  |  CED Clinic Oncology[Substance Use](https://cedclinic.com/stroke-risk-assessment-substance-use/)CannabisSupportive Care[Treatment Adherence](https://cedclinic.com/2026-cannabis-wholesale-tax-impact-michigan/) Journal Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer Study Type Observational Study Population Human participants Why This Matters This comprehensive review addresses a critical gap in oncology practice where [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) patterns—from therapeutic cannabis to problematic alcohol use—significantly influence cancer treatment outcomes. Understanding these relationships is essential for optimizing supportive care strategies and [treatment adherence](https://cedclinic.com/2026-cannabis-wholesale-tax-impact-michigan/) in cancer patients. Clinical Summary This narrative review synthesized evidence from January 2010 to April 2025 examining how alcohol, tobacco, cannabis, and opioids affect cancer care outcomes including diagnosis timing, treatment adherence, toxicity, and survival. Heavy alcohol use and continued tobacco use demonstrated clear associations with delayed diagnosis, poorer adherence, increased toxicity, and inferior survival outcomes. Cannabis and opioid evidence was more heterogeneous and predominantly observational, with interpretation limited by varied exposure definitions and study methodologies. The review highlights the complex interplay between substance use patterns and cancer care across the treatment continuum. Dr. Caplan’s Take “This review confirms what we observe clinically—substance use profoundly shapes cancer outcomes, but our understanding remains frustratingly incomplete for cannabis and opioids where patients need clearer guidance. The heterogeneity in [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) particularly underscores the urgent need for standardized exposure metrics in oncology studies.” Clinical Perspective 🧠 Clinicians should systematically assess all substance use patterns in cancer patients, recognizing that alcohol and tobacco cessation interventions have established benefit. For cannabis and opioid use, individualized risk-benefit discussions are warranted given the limited and heterogeneous evidence base. Supportive care teams should integrate substance use assessment into routine oncology care to optimize treatment outcomes. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Substance%20use%20in%20supportive%20oncology%20and%20its%20impact%20on%20clinical%20outcomes%20and%20car...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41888431/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41888431/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Substance%20use%20in%20supportive%20oncology%20and%20its%20impact%20on%20clinical%20outcomes%20and%20car...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41888431/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41888431/](https://pubmed.ncbi.nlm.nih.gov/41888431/) Table of Contents - [FAQ](#FAQ)[How does cannabis use affect cancer treatment outcomes compared to alcohol and tobacco?](#How_does_cannabis_use_affect_cancer_treatment_outcomes_compared_to_alcohol_and_tobacco) - [Should I be concerned about my patient’s cannabis use during cancer treatment?](#Should_I_be_concerned_about_my_patient8217s_cannabis_use_during_cancer_treatment) - [Does cannabis use affect chemotherapy adherence in cancer patients?](#Does_cannabis_use_affect_chemotherapy_adherence_in_cancer_patients) - [Can cannabis use influence cancer diagnosis timing?](#Can_cannabis_use_influence_cancer_diagnosis_timing) - [How should oncologists approach substance use screening in their cancer patients?](#How_should_oncologists_approach_substance_use_screening_in_their_cancer_patients) - [Related](#Related) ## FAQ #### How does cannabis use affect cancer treatment outcomes compared to alcohol and tobacco? Unlike alcohol and tobacco which show well-established negative impacts on cancer outcomes, the evidence for cannabis is heterogeneous and predominantly observational. Heavy alcohol use and continued tobacco use are consistently associated with delayed diagnosis, poorer treatment adherence, greater toxicity, and inferior survival. Cannabis effects remain unclear due to variability in study designs and exposure definitions. #### Should I be concerned about my patient’s cannabis use during cancer treatment? While the evidence is mixed, [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) warrants clinical attention as part of comprehensive substance use assessment in cancer patients. The study indicates that substance use across the spectrum can impact diagnostic timing, treatment adherence, toxicity profiles, and symptom burden. Regular monitoring and open discussion with patients about all substance use is recommended. #### Does cannabis use affect chemotherapy adherence in cancer patients? The study identifies treatment adherence as a key outcome affected by substance use, though specific evidence for cannabis impact on adherence appears limited and heterogeneous. Unlike alcohol and tobacco which show clear negative effects on adherence, cannabis effects on treatment compliance require further research. Clinicians should assess and monitor adherence patterns in cannabis-using patients. #### Can cannabis use influence cancer diagnosis timing? While heavy alcohol and tobacco use are associated with delayed cancer diagnosis, the evidence for cannabis impact on diagnostic timing is not well-established according to this review. The heterogeneous nature of [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) makes it difficult to draw definitive conclusions. However, any substance use should be considered when evaluating factors that might affect healthcare engagement and diagnostic processes. #### How should oncologists approach substance use screening in their cancer patients? Given that substance use spans a continuum and can shape outcomes across the cancer care continuum, comprehensive screening for alcohol, tobacco, cannabis, and opioids should be standard practice. The study emphasizes that substance use affects multiple domains including symptom burden, treatment toxicity, and survival outcomes. Regular assessment allows for appropriate supportive interventions and monitoring. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Substance use in supportive oncology and its impact on clinical outcomes and care.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41888431/”, “about”: “supportive care cancer official journal multinational”, “isPartOf”: “Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabis Use Patterns and Perception of Acute Pain](https://cedclinic.com/acute-pain-cannabinoid-withdrawal-sex-dependent-cannabis-study/) Explore sex-dependent associations between [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and acute pain perception during brief abstinence periods. [Read More](https://cedclinic.com/acute-pain-cannabinoid-withdrawal-sex-dependent-cannabis-study/) [Alcohol, Tobacco, and Opioid Addictions Share Genetic Roots](https://cedclinic.com/shared-genetic-vulnerability-substance-use-disorders/) Learn about the shared genetic factors underlying common substance addictions and their implications for treatment. [Discover Insights](https://cedclinic.com/shared-genetic-vulnerability-substance-use-disorders/) [Is Cannabis Effective for Treating Mental Health Disorders?](https://cedclinic.com/cannabis-mental-health-treatment-challenges/) Review current evidence on cannabis use and its potential role in managing [mental health](https://cedclinic.com/cannabis-psychiatric-research-findings-depression-anxiety/) conditions. [Explore Research](https://cedclinic.com/cannabis-mental-health-treatment-challenges/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).